Schölmerich J, Zimmermann U, Köttgen E, Volk B A, Hasler C, Diener W, Gerok W
Klin Wochenschr. 1987 Jul 15;65(14):639-42. doi: 10.1007/BF01875498.
Fibrinolysis induced by the infusion of plasminogen activators into the circulation has been shown to cause coagulation disorders in ascites retransfusion. Dexamethasone is known to inhibit the synthesis of plasminogen activators by peritoneal macrophages. We therefore assessed its potential in preventing the occurrence of fibrinolysis by injecting 16 mg dexamethasone intraperitoneally in 10 patients 24 h before ascites retransfusion was performed. In addition, the effect of dexamethasone upon the activity or concentration of several proteases and antiproteases related to coagulation in plasma and ascites was analyzed on 15 occasions. An increase of the activity of plasminogen, alpha 2-antiplasmin, and antithrombin III, and in the concentration of alpha 1-protease inhibitor in ascites was induced by the dexamethasone injection. However, the reaction was not identical in all patients. Those patients having an increase of plasminogen activities of 0.6 CTA U/ml or more did not show signs of fibrinolysis during retransfusion. The results obtained indicate that intraperitoneal injection of dexamethasone decreases the concentration of plasminogen activators in ascites and thereby reduces the risk of coagulation disorders during retransfusion procedures. Since the effect is variable and not sustained, assessment of preoperative plasminogen concentrations is mandatory in order to prevent complications.
已证实在腹水回输过程中,向循环系统输注纤溶酶原激活剂所诱导的纤维蛋白溶解会导致凝血障碍。已知地塞米松可抑制腹膜巨噬细胞合成纤溶酶原激活剂。因此,我们在10例患者进行腹水回输前24小时腹腔注射16毫克地塞米松,评估其预防纤维蛋白溶解发生的潜力。此外,还在15个病例中分析了地塞米松对血浆和腹水中几种与凝血相关的蛋白酶和抗蛋白酶活性或浓度的影响。注射地塞米松可使腹水中纤溶酶原、α2-抗纤溶酶和抗凝血酶III的活性以及α1-蛋白酶抑制剂的浓度增加。然而,并非所有患者的反应都相同。纤溶酶原活性增加0.6 CTA U/ml或更多的患者在回输过程中未出现纤维蛋白溶解的迹象。所得结果表明,腹腔注射地塞米松可降低腹水中纤溶酶原激活剂的浓度,从而降低回输过程中发生凝血障碍的风险。由于效果不恒定且不能持续,为预防并发症,术前必须评估纤溶酶原浓度。